Introducing of neoadjuvant chemotherapy (NCT) in breast cancer patient may be associated with changes in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) status. Method: In our prospective cohort study, we evaluated the impact of change in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) on the prognosis of breast cancer patients treated with neoadjuvant chemotherapy (NCT). We investigated 110 patients with locally advanced breast cancer for ER, PR and HER2 status of their lesions before and after NCT. Result: For hormone receptor status (HR)(which include ER,PR) of the patients after receiving NCT, 12(10.9%) of them changed from HR (+) to HR (−) and 15 (13.6%) changed from HR (−) to HR (+). For HER2 status after NCT 8 (7.3%) patients changed from HER2 (+) to HER2 (−) and 9 (8.2%) patients changed from HER2 (−) to HER2 (+). Triple negative (TN) tumor phenotype changes occurred in 17 (15.5%) patients. Patients whom HR status has been changed from positive to negative had poor prognosis for both disease-free (DFS) survival and overall survival (OS) in univariate survival analysis Conclusion: changes in ER, PR, HER2 status and tumor phenotype in breast cancer patients after NCT have negative prognostic impact and were associated with a poor prognosis.